VALEO PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.095 CAD | -5.00% |
|
-17.39% | -47.22% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
Presenter SpeechSteven Saviuk (Executives)I'd like you to welcome you to our annual meeting, w...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-07-03
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.1
CAD
Average target price
0.5
CAD
Spread / Average Target
+400.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.22% | 6.85M | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +16.34% | 239B | |
| +6.68% | 204B | |
| -9.08% | 198B | |
| +8.62% | 168B |
- Stock Market
- Equities
- VPH Stock
- News Valeo Pharma Inc.
- Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call